+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Gliosarcoma - Pipeline Review, H1 2015

  • ID: 3330526
  • Report
  • June 2015
  • 62 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Sanofi
  • MORE
Gliosarcoma - Pipeline Review, H1 2015

Summary

This, ‘Gliosarcoma - Pipeline Review, H1 2015’, provides an overview of the Gliosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gliosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gliosarcoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gliosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gliosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gliosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gliosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gliosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • Celgene Corporation
  • Merck & Co., Inc.
  • Sanofi
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Gliosarcoma Overview
Therapeutics Development
Pipeline Products for Gliosarcoma - Overview
Pipeline Products for Gliosarcoma - Comparative Analysis
Gliosarcoma - Therapeutics under Development by Companies
Gliosarcoma - Therapeutics under Investigation by Universities/Institutes
Gliosarcoma - Pipeline Products Glance
Clinical Stage Products
Gliosarcoma - Products under Development by Companies
Gliosarcoma - Products under Investigation by Universities/Institutes
Gliosarcoma - Companies Involved in Therapeutics Development
Amgen Inc.
Burzynski Research Institute, Inc.
Celgene Corporation
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Sanofi
Gliosarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antineoplaston Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
indoximod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lonafarnib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oncolytic Virus to Target IL-12 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rilotumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SGT-53 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gliosarcoma - Recent Pipeline Updates
Gliosarcoma - Dormant Projects
Gliosarcoma - Product Development Milestones
Featured News & Press Releases
Nov 26, 2013: Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Gliosarcoma, H1 2015
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Gliosarcoma - Pipeline by Amgen Inc., H1 2015
Gliosarcoma - Pipeline by Burzynski Research Institute, Inc., H1 2015
Gliosarcoma - Pipeline by Celgene Corporation, H1 2015
Gliosarcoma - Pipeline by Merck & Co., Inc., H1 2015
Gliosarcoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Gliosarcoma - Pipeline by NewLink Genetics Corporation, H1 2015
Gliosarcoma - Pipeline by Sanofi, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Gliosarcoma Therapeutics - Recent Pipeline Updates, H1 2015
Gliosarcoma - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Gliosarcoma, H1 2015
Number of Products under Development for Gliosarcoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
Amgen Inc.
Burzynski Research Institute, Inc.
Celgene Corporation
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
NewLink Genetics Corporation
Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll